Kura Oncology stockholders approve 5.5M share increase to equity plan at June 5 annual meeting

Kura Oncology, Inc.

Stockholders approved Amended 2014 Plan, increasing authorized shares by 5.5M to total 29,827,686 shares.
Troy E. Wilson and Faheem Hasnain elected as Class I directors until 2027 annual meeting.
Ratification of Ernst & Young as auditor for FY2024 approved (69.6M for, 56.7K against).
Advisory vote on executive compensation approved with 61.5M for, 5.4M against.
About 69.8M of 76.2M outstanding shares were represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.